Cargando…
Strategy toward Kinase-Selective Drug Discovery
[Image: see text] Kinase drug selectivity is the ground challenge in cancer research. Due to the structurally similar kinase drug pockets, off-target inhibitor toxicity has been a major cause for clinical trial failures. The pockets are similar but not identical. Here, we describe a transformation i...
Autores principales: | Zhang, Mingzhen, Liu, Yonglan, Jang, Hyunbum, Nussinov, Ruth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2023
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10018734/ https://www.ncbi.nlm.nih.gov/pubmed/36815703 http://dx.doi.org/10.1021/acs.jctc.2c01171 |
Ejemplares similares
-
Higher‐order interactions of Bcr‐Abl can broaden chronic myeloid leukemia (CML) drug repertoire
por: Liu, Yonglan, et al.
Publicado: (2023) -
AlphaFold, Artificial
Intelligence (AI), and Allostery
por: Nussinov, Ruth, et al.
Publicado: (2022) -
Activation mechanisms of clinically distinct B‐Raf V600E and V600K mutants
por: Zhang, Mingzhen, et al.
Publicado: (2022) -
PI3K inhibitors: review and new strategies
por: Zhang, Mingzhen, et al.
Publicado: (2020) -
The mechanism of activation of MEK1 by B-Raf and KSR1
por: Maloney, Ryan C., et al.
Publicado: (2022)